ArticleEuropean journal of clinical nutrition2026
Increasing levels of industrially derived trans fatty acids in European erythrocytes.
Article in European journal of clinical nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combined erythrocyte levels of C18:1t, 18:2tc, 18:2tt, and 18:2ct (or industrially-produced trans fatty acids, IP-TFA) > 1.04% are associated with increased mortality, as compared with lower levels. In the United States, mean erythrocyte levels of IP-TFA declined from 2009 to 2016, with a parallel decline in mortality. In Europe, in 2014 and 2015, only 1.3% of erythrocyte samples had levels of IP-TFA > 1.04%. However, recently IP-TFA levels increased, driven only by increases of 18:1t. In 2024, in 2.12% of 20,510 samples, IP-TFA were >1.04%; in 2025, in 4.47% of 27,834 samples; in January - June 2026, in 7.21% of 18,577 samples (p for trend <0.001). Since levels of C16:1n7t, a marker of dairy intake like vaccenic acid (C18:1t-11), remained constant from 2020 to 2026, we assume the increase to be driven mainly by elaidic acid (C18:1t-9), detected, e.g., in adulterated olive oil. This increase is likely to be associated with increased mortality in Europe.
Identifiers
42661050What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.